America has a new weight-loss drug, and it’s a pill

Eli Lilly (LLY) is at a pivotal technical juncture, as the FDA approval of *Foundayo* serves as a fundamental catalyst that conflicts with a severely oversold RSI of 22.97. The recent surge of positive news—comprising the oral GLP-1 approval and the $7.8B acquisition of Centessa—suggests a transition from a period of distributive price exhaustion to a potential institutional accumulation phase. With the MACD signaling a bullish crossover beneath the zero line, the stock is showing early signs of a reversal; however, investors should monitor the $950 support level closely, as a failure to hold this base could exacerbate the current "oversold" narrative. Fundamental filings indicate robust R&D spending, confirming that Lilly is actively prioritizing its TAM expansion, which currently offsets the negative sentiment stemming from UK pricing disputes. Given the current 1.17x volume, traders should look for a confirmed daily close above $975 to validate a trend reversal, while utilizing the $22.95 ATR to set stop-losses below the $930 psychological floor. Confluence between the bullish drug pipeline narrative and the oversold technical status creates a high-conviction "Buy on Dips" setup for long-term holders, provided the market maintains its current volume support.